Arqule Inc.
- ARQL
- NASDAQ
- Consumer Products
- Latest 2.75
- Currency US$
- Change 0.04
- Percent Change 1.476 %
- Volume 167,182
- Thu May 23, 2013 4:00 PM EDT NASDAQ data delayed 15 minutes.
The Globe and Mail
- Open 2.67
- Previous Close 2.71
- High 2.81
- Low 2.65
- Bidx20 2.66
- Askx10 3.25
- 52-week High -- 6.98
- 52-week Low -- 1.98
- Beta 0.938
- Market Cap 172.86M
- EPS -0.20
- P/E --
- Forward P/E --
- PEG --
- Annual Dividend --
- Yield --
News
- ArQule Reports First Quarter 2013 Financial Results
- ArQule to Report First Quarter 2013 Financial Results on May 8, 2013
- ArQule, Inc. to Present at Needham 12th Annual Healthcare Conference
- ArQule's Novel AKT Pathway Inhibitor, ARQ 092, Demonstrates Safety, Target Inhibition in Phase 1 Trial
- ArQule Regains Worldwide Rights to AKT Program
Financials & Calendars
- Sales $33,570,000
- Earnings $-12,390,000
- Return on Equity n/a
- Cash Flow --
- Cash $14,970,000
- Current Ratio 3.68
12 months ended Mar 31, 2013.
Trailing 12 month results shown above.
All data is in U.S. dollars.
- Assets $123,400,000
- Liabilities $46,770,000
- Liabilities-to-Equity Ratio 0.61
Price Ratios
- Price to Sales 5.15
- Price to Book 2.26
- Price to Cash Flow n/a
Event Calendar
| Event | Last | Next | ||
|---|---|---|---|---|
| Earnings | May 8 | $-0.11 | Aug 8 | $-0.11 |
| Surprises | May 8 | -18.18% | n/a | n/a |
| Dividends | n/a | n/a | n/a | n/a |
| Splits | n/a | -- | n/a | n/a |
12 months ended May 23, 2013.
A look at major corporate events and financial announcements that are coming up.
Company Information
About the Company
ArQule, Inc. is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company's targeted, broad-spectrum products and research programs are focused on key biological processes that are central to cancer. ArQule's lead clinical-stage products have been generated from two scientific platforms: Cancer Survival Protein modulation and Activated Checkpoint Therapy. The Cancer Survival Protein modulation platform has generated a clinical-stage product that mediates its effects by inhibiting the activity of a molecule known as c-Met, which plays multiple roles in cancer cell growth, survival, invasion, angiogenesis and metastasis. The ACT platform is designed to kill cancer cells selectively while sparing normal cells through direct activation of DNA damage response/checkpoint pathways. The Company's lead ACT program, based on the E2F-1 pathway, is partnered with Roche.
Officers
- Patrick J. Zenner Chairman
- Paolo Pucci Chief Executive Officer
- Company Type: n/a
- Company Status: n/a
- Full-time Employees: n/a
-
Incorporation:
United States,
n/a -
Top 1000 Ranking:
Profit: n/a
Revenue: n/a
Assets: n/a
Head Office
19 PRESIDENTIAL WAYWOBURN, MA
01801
Phone: (781)-994-0300
Fax: (781)-3766019
Ideas & Discussion
Live Discussion of ARQL on StockTwits